ABOUT
Compound druggability evaluation- Druggability refer to the properties of compounds with the potential to be developed into drug which has been performed the preliminary pharmacodynamic study and early evaluation of pharmacokinetic properties and safety. Translational research helps to build a systematic R&D chain from basic research, preclinical research and clinical efficacy evaluation to new drug manufacturing and clinical application of innovative drugs, to smooth the interaction of the information and the research between basic medicine science and biology and the R&D of innovative drug and clinical medicine, to shorten the research and development cycle of innovative drugs from laboratory synthesis to clinical application. The process of new drug research is lengthy, high-risk and high-reward. Medicilon provides druggability evaluation services which is the most effective method to reduce the risk. The druggability of new drug creation includes: druglikeness, physicochemical properties, biochemical properties, pharmacokinetics and toxicity, etc.In the process of new drug development and clinical application, the various parameters of in-vivo process of a compound (absorption, distribution, metabolism, excretion, ADME (toxic pharmacokinetics)) is an important indicator of its druggability.
